|Bid||22.90 x 900|
|Ask||22.92 x 1300|
|Day's range||21.02 - 22.98|
|52-week range||5.84 - 24.42|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||20.82|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||16 May 2022|
|1y target est||N/A|
Many investors likely hadn't heard of drugmaker Siga Technologies (NASDAQ: SIGA) even just a month ago. Siga, which owns a monkeypox treatment in Tpoxx, is likely to experience a surge in sales. The big question for investors: Is Siga's stock destined to go even higher or has it already peaked?
A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.
SIGA Technologies, maker of the only available monkeypox treatment, is working to ramp up manufacturing for broader global distribution.